Abstract
The diversity of membrane-initiated progesterone actions has made characterization and establishment of its biological importance a complicated endeavor. A new study by Zuo and colleagues shows that progesterone via endogenous membrane progesterone receptor-α acts as a negative regulator of proliferation and epithelial to mesenchymal transition in a breast cancer cell line. These progesterone-mediated actions appear to be regulated through epidermal growth factor receptor and phosphatidylinositol 3-kinase signaling localized in caveolae. Moreover, the study shows expression of membrane progesterone receptor-α in benign and malignant breast cancer tissues. These data bring forth novel concepts with regard to progesterone actions in the breast; however, further work is warranted to fully characterize the physiologic actions of extra-nuclear progesterone signaling in the breast. data ranging from fi sh to human has shown that mPRs can modulate MAPK signaling, cAMP levels, and calcium signaling in response to progesterone [2, 3, 7, 9] . Interestingly, despite having essentially no sequence homology to G protein-coupled receptors, some computer modeling programs predict mPRs to contain seven transmembrane domains [10] . Moreover, studies suggest that these receptors regulate cAMP levels via G-protein coupled signaling at the plasma membrane [3, 9] . However, this characterization of mPRs is seriously debated by studies questioning the ability of mPRs to localize to the plasma membrane, bind to progesterone, or regulate G-protein signaling [4, 5] . In addition, a recent study in yeast showed progesterone-induced signaling to be G-protein independent [11] . Th us, the functional and biological roles of the mPR family remain murky.
Despite the fair share of controversies, given the importance of progesterone actions within and outside the reproductive system, especially in the breast, mPRs remain an attractive target for therapeutic intervention and therefore a subject of intense research. Th e article by Zuo and colleagues [1] provides new and provocative insight into the role of mPRs in epithelial to mesenchymal transition (EMT), a diff erentiation process characteristic of basal phenotype breast cancer. Th e authors propose that progesterone acts as a negative regulator of EMT in a breast cancer cell line through mPRα-mediated mechanisms whereby mPRα interacts with the epidermal growth factor receptor and caveolin-1 in the caveolar membrane, leading to subsequent inactivation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and inhibition of EMT-relevant events as well as proliferation. Th e authors further provide evidence of mPRα expression in benign and malignant human breast tissue, with especially high levels in triple-negative (no detectable estrogen receptor, PR, or Her2/neu) breast cancers. Th ese observations bring forth the possibility that proges tin therapy may be benefi cial in triple-negative breast cancers, where their anti-EMT and anti-proliferative eff ects may be most potent.
To date, there is limited physiological evidence of mPR actions. mPRs have been implicated to have a role in the uterus [3, 7, 9] and in the negative feedback actions of proges terone on the release of gonadotropin-releasing hormone [12] . Th is study by Zuo and colleagues provides the stepping stone for establishing another biological importance of mPRs in humans. However, like many scientifi c discoveries, the results create perhaps more questions than answers. First, the model proposed in this study indicates that the anti-EMT eff ects of progesterone are mediated via mPRα by inhibition of PI3K, yet progestins are known to activate the PI3K/Akt in many other instances [13, 14] . In fact, in the supplemental data the authors show that progesterone activates Akt phosphorylation in their cells. Second, the authors describe a negative eff ect of progesterone via mPRα on MB468 cell proliferation, while others have reported a proliferative eff ect of PGRMC1 in the same cell type [15] . Th us, the question arises whether progesterone has both proliferative and anti-proliferative eff ects in breast cancer cells, depending upon the cell line and experimental setup. Th ird, the cells used in this study have low, but still detectable, levels of classical PR, the expression of which rises upon progesterone treatment. In addition, expression of PGRMC1 was not investigated. Th erefore, it is still unclear whether mPRα functions as a standalone PR, or whether it works together with other receptors to regulate proliferation and EMT. Finally, the true biological importance of mPR signaling in breast cancer development, or for that matter, in any process, cannot be properly assessed until the development of better in vivo model systems, including the creation of mPR knockout mouse models. Until then the murky waters of progesterone signaling in the membrane will remain treacherous.
Abbreviations EMT = epithelial to mesenchymal transition; MAPK = mitogen-activated protein kinase; mPR = membrane progesterone receptor; PGMRC1 = progesterone membrane receptor component-1; PI3K = phosphatidylinositol 3-kinase; PR = progesterone receptor.
